

Methamphetamine (METH) is a psychostimulant drug of abuse that causes severe brain damage. However, the mechanisms responsible for these effects are poorly understood, particularly regarding the impact of METH on hippocampal neurogenesis. Moreover, neuropeptide Y (NPY) is known to be neuroprotective under several pathological conditions. Here, we investigated the effect of METH on dentate gyrus (DG) neurogenesis, regarding cell death, proliferation and differentiation, as well as the role of NPY by itself and against METH-induced toxicity. DG-derived neurosphere cultures were used to evaluate the effect of METH or NPY on cell death, proliferation or neuronal differentiation. Moreover, the role of NPY and its receptors (Y1, Y2 and Y 5) was investigated under conditions of METH-induced DG cell death. METH-induced cell death by both apoptosis and necrosis at concentrations above 10 nM, without affecting cell proliferation. Furthermore, at a non-toxic concentration (1 nM), METH decreased neuronal differentiation. NPY's protective effect was mainly due to the reduction of glutamate release, and it also increased DG cell proliferation and neuronal differentiation via Y1 receptors. In addition, while the activation of Y1 or Y2 receptors was able to prevent METH-induced cell death, the Y1 subtype alone was responsible for blocking the decrease in neuronal differentiation induced by the drug. Taken together, METH negatively affects DG cell viability and neurogenesis, and NPY is revealed to be a promising protective tool against the deleterious effects of METH on hippocampal neurogenesis. © 2011 Elsevier Ltd. All rights reserved.
| EMTREE drug terms: | glutamic acidmethamphetamineneuropeptide Yneuropeptide Y1 receptorneuropeptide Y2 receptorneuropeptide Y5 receptor |
|---|---|
| EMTREE medical terms: | animal cellanimal tissueapoptosisarticlecell proliferationcell viabilityconcentration responsecontrolled studydentate gyrusmousenerve cell differentiationnerve cell necrosisneuroanatomyneuroprotectionneurosphereneurotoxicitynonhumanpriority journalprotein analysisprotein functionreceptor upregulation |
glutamic acid, 11070-68-1, 138-15-8, 56-86-0, 6899-05-4; methamphetamine, 28297-73-6, 51-57-0, 537-46-2, 7632-10-2; neuropeptide Y, 82785-45-3, 83589-17-7
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| Programa Operacional Temático Factores de Competitividade | ||
| Fuel Cell Technologies Program | FCT | |
| Federación Española de Enfermedades Raras | FEDER | |
| SFRH/BD/63773/2009,04/09,SFRH/BD/35893/2007 |
This work was supported by Projects PTDC/SAU-FCF/098685/2008, PTDC/SAU-NEU/101783/2008, PTDC/SAU-NEU/104415/2008 (COMPETE and FEDER funds), GAPI Project 04/09 and fellowships SFRH/BD/63773/2009 and SFRH/BD/35893/2007 from FCT , Portugal, co-financed by QREN .
Silva, A.P.; Laboratory of Pharmacology and Experimental Therapeutics, Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, Portugal;
© Copyright 2018 Elsevier B.V., All rights reserved.